Immunoassay News and Research

RSS

Accurate rapid-testing device displays antibody levels in an easily readable way

Vaccines have become the most important weapon in the fight against the COVID-19 pandemic, but antibody levels after vaccination decay quickly over time.

28 Jul 2022

The kinetics of SARS-CoV-2 nucleocapsid antibodies up to 21 months after infection

Researchers found significant seroreversion of total anti-nucleocapsid immunoglobulin.

28 Jul 2022

Pfizer’s SARS-CoV-2 vaccine does not affect the honeymoon phase of type 1 diabetes

In a new study, researchers reported that Pfizer’s BNT162b2 vaccine against severe acute respiratory syndrome coronavirus 2 does not affect the honeymoon phase of type 1 diabetes (T1D).

13 Jul 2022

Immunogenicity and safety of the protein-based heterodimer booster vaccine for COVID-19

Researchers compared the immunogenicity and safety of the protein-based heterodimer vaccine (PHH-1V) and BNT162b2 COVID-19 vaccines.

8 Jul 2022

Evaluation of antinucleocapsid antibody seropositivity following SARS-CoV-2 infection in vaccinated individuals

A new study assessed both placebo and vaccine recipients in the mRNA-1273 (Moderna) phase 3 clinical trial who were infected with SARS-CoV-2 during the blinded, placebo-controlled trial phase.

6 Jul 2022

New antibody-based method for SARS-CoV-2 detection does not require a blood sample

Despite significant and stunning advances in vaccine technology, the COVID-19 global pandemic is not over. A key challenge in limiting the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is identifying infected individuals.

1 Jul 2022

Epigenome-wide DNA methylation patterns in convalescent COVID-19 subjects

Researchers investigated the epigenetic rewiring of odor perception in SARS-CoV-2-infected cells.

29 Jun 2022

A cancer patient who had SARS-CoV-2 for over eight months

In a recent study posted to the medRxiv* pre-print server, researchers in Israel described the case of a severely immunocompromised cancer patient who developed a chronic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

28 Jun 2022

Investigating PREVENT-19 trial findings of serological correlates of immune protection and risk against COVID-19

Researchers presented the PREVENT-19 phase 3 trial findings on the effectiveness of the NVX-CoV2373 adjuvanted, recombinant S nanoparticle vaccine.

27 Jun 2022

Demonstrating varying pathogenicity and tropism of SARS-CoV-2 variants in a feline model

In a recent study posted to the bioRxiv* pre-print server, researchers at Cornell University College of Veterinary Medicine and the University of Illinois Urbana-Champaign compared the infection dynamics, pathogenicity, and tissue tropism of multiple severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants in adult cats.

17 Jun 2022

Natural serological evidence of SARS-CoV-2 infection in lactating cows

Researchers observed SARS-CoV-2 seroconversion in lactating cows.

7 Jun 2022

Mucosal COVID vaccine candidate powerfully protective in macaques

A recent research paper posted to the bioRxiv* preprint server illustrated the protective efficacy of the intranasal pediatric parainfluenza virus-vectored coronavirus disease 2019 (COVID-19) vaccine prospect, B/HPIV3/S-6P, in macaques.

26 May 2022

Study measures viral antigen and inflammatory biomarkers in CSF of COVID-19 patients in relation to neurologic symptoms and disease severity

Researchers investigated the impact of coronavirus disease 2019 (COVID-19) on biomarkers in the cerebrospinal fluid (CSF).

25 May 2022

Gut microbiota linked to immunocompromised people's variable response to SARS-CoV-2 vaccination

In a recent study posted to the Research Square* preprint server, researchers assessed whether disturbances in the gut microbiota weaken the serological response to the coronavirus disease 2019 (COVID-19) vaccine in inflammatory bowel disease (IBD) patients.

25 May 2022

Immunoassay News and Research

Accurate rapid-testing device displays antibody levels in an easily readable way

The kinetics of SARS-CoV-2 nucleocapsid antibodies up to 21 months after infection

Pfizer’s SARS-CoV-2 vaccine does not affect the honeymoon phase of type 1 diabetes

Immunogenicity and safety of the protein-based heterodimer booster vaccine for COVID-19

Evaluation of antinucleocapsid antibody seropositivity following SARS-CoV-2 infection in vaccinated individuals

New antibody-based method for SARS-CoV-2 detection does not require a blood sample

Epigenome-wide DNA methylation patterns in convalescent COVID-19 subjects

A cancer patient who had SARS-CoV-2 for over eight months

Investigating PREVENT-19 trial findings of serological correlates of immune protection and risk against COVID-19

Demonstrating varying pathogenicity and tropism of SARS-CoV-2 variants in a feline model

Natural serological evidence of SARS-CoV-2 infection in lactating cows

Mucosal COVID vaccine candidate powerfully protective in macaques

Study measures viral antigen and inflammatory biomarkers in CSF of COVID-19 patients in relation to neurologic symptoms and disease severity

Gut microbiota linked to immunocompromised people's variable response to SARS-CoV-2 vaccination

Anti-SARS-CoV-2 titers predict COVID severity

Serologic response to SARS-CoV-2 may predict COVID-19 severity

T-cell responses after COVID-19 and vaccinations

Study assesses the efficacy and safety of lithium treatment in patients infected with severe SARS-CoV-2

Mologic and Alamar Biosciences collaborate to develop a next generation COVID-19 antigen test

Study suggests aerosol transmission of antibodies may contribute to host protection against SARS-CoV-2

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News